Release Date: October 31, 2025
Expiration Date: October 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in neuromuscular disease, with a focus on Duchenne muscular dystrophy (DMD). In this educational program, these experts address unmet needs in DMD, focusing on developing an understanding of the underlying pathophysiological pathways and emerging pharmacological strategies. The importance of an individualized, multidisciplinary approach in managing comorbidities, coordinating care within the health care team, and educating patients and caregivers is also addressed.
This educational activity is an archive of the live symposium held on September 27, 2025.
Target Audience
This educational activity is directed toward neuromuscular disease specialists, neurologists, specialty nurse practitioners, specialty physician assistants, nurses, and other health care practitioners involved in the care of patients with neuromuscular disorders.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify the role of dystrophin disruption in the pathophysiology of Duchenne muscular dystrophy
- Evaluate clinical trial data for new and investigational agents for Duchenne muscular dystrophy
- Design multidisciplinary treatment plans for patients with Duchenne muscular dystrophy
Anne M. Connolly, MD, FAAN
Robert F. and Edgar T. Wolfe Endowed Chair
Professor of Pediatrics and Neurology
Chief of Pediatric Neurology
Nationwide Children’s Hospital
Columbus, OH
Disclosures:
Advisor, Site PI: Edgewise, Sarepta Therapeutics; Data
Management Safety Board: Avidity Therapeutics, Octapharma; Site Subi:
Biohaven, Novartis, Scholar Rock
Amy Moore, PhD
Research Statistician
RTI International
Waltham, MA
Disclosures: Amy Moore, PhD, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here